litlas
Log inCreate account

Thomas Bachelot

Active 1994–2025

Also published as
Thomas BACHELOT
138
Papers
26,129
Citations
79
h-index
128
i10-index

Citations

Citations per year for Thomas Bachelot1964: 1 citations1993: 6 citations1995: 1 citations1996: 2 citations1998: 2 citations1999: 3 citations2000: 10 citations2001: 15 citations2002: 10 citations2003: 9 citations2004: 11 citations2005: 12 citations2006: 20 citations2007: 20 citations2008: 24 citations2009: 43 citations2010: 50 citations2011: 74 citations2012: 149 citations2013: 227 citations2014: 196 citations2015: 219 citations2016: 217 citations2017: 221 citations2018: 267 citations2019: 860 citations2020: 1,104 citations2021: 1,196 citations2022: 979 citations2023: 875 citations2024: 1,392 citations2025: 799 citations2026: 27 citations1965–1992: no citations, so these years are not shown1994: no citations, so this year is not shown1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,840 citing papers, 21.8% of this breakdownChina: 1,277 citing papers, 9.8% of this breakdownItaly: 914 citing papers, 7% of this breakdownFrance: 880 citing papers, 6.8% of this breakdownUnited Kingdom: 671 citing papers, 5.2% of this breakdownGermany: 628 citing papers, 4.8% of this breakdownSpain: 542 citing papers, 4.2% of this breakdownCanada: 433 citing papers, 3.3% of this breakdownBelgium: 378 citing papers, 2.9% of this breakdownSwitzerland: 375 citing papers, 2.9% of this breakdownJapan: 352 citing papers, 2.7% of this breakdownNetherlands: 328 citing papers, 2.5% of this breakdown
0%21.8%Other 26.1%

Institutions

Fields

  • Medicine60.8%
  • Biochemistry, Genetics and Molecular Biology27.3%
  • Immunology and Microbiology7.8%
  • Neuroscience1.3%
  • Computer Science0.8%
  • Engineering0.5%
  • Other1.5%

Topics

  • Advanced Breast Cancer Therapies8%
  • HER2/EGFR in Cancer Research6.5%
  • Breast Cancer Treatment Studies4.9%
  • Cancer Immunotherapy and Biomarkers4.5%
  • Cancer Genomics and Diagnostics3.9%
  • Immunotherapy and Immune Responses2.8%
  • Other69.4%

Coauthors

All papers

Open in search
  1. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Sibylle Loibl, Fabrice André, Thomas Bachelot, Carlos H. Barrios, Jonas Bergh, Harold J. Burstein, Maria João Cardoso, Lisa A. Carey, Shaheenah Dawood, Lucia Del Mastro, Carsten Denkert, Eva Maria Fallenberg, Prudence A. Francis, H. Gamal‐El‐Din, Karen A. Gelmon, Charles E. Geyer, Michael Gnant, Valentina Guarneri, Sudeep Gupta, Sung‐Bae Kim, David Krug, Miguel Martín, Icro Meattini, Monica Morrow, Wolfgang Janni, Shani Paluch–Shimon, Ann H. Partridge, Philip Poortmans, Lajos Pusztai, Meredith M. Regan, Joseph A. Sparano, Tanja Španić, Sandra M. Swain, Sergei Tjulandin, Masakazu Toi, Dario Trapani, Andrew Tutt, B. Xu, Giuseppe Curigliano, Nadia Harbeck - Annals of Oncology 2023 cited by 844

  2. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

    Authors: Fernanda Mosele, Élise Deluche, Amélie Lusque, Loïc Le Bescond, Thomas Filleron, Yoann Pradat, Agnès Ducoulombier, Barbara Pistilli, Thomas Bachelot, F. Viret, Christelle Lévy, Nicolas Signolle, Alexia Alfaro, Diep Thi Ngoc Tran, Ingrid Garberis, Hugues Talbot, Stergios Christodoulidis, Maria Vakalopoulou, Nathalie Droin, Aurelie Stourm, Maki Kobayashi, Tomoya Kakegawa, Ludovic Lacroix, Patrick Saulnier, Bastien Job, Marc Deloger, Marta Jimenez, Céline Mahier - Aït Oukhatar, Vianney Baris, Pierre Laplante, Patricia Kannouche, Virginie Marty, Magali Lacroix‐Triki, Véronique Dièras, Fabrice André - Nature Medicine 2023 cited by 370

  3. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 cited by 2,009

  4. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    Authors: José Baselga, Mario Campone, Martine Piccart, Howard A. Burris, Hope S. Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I. Pritchard, Fabienne Lebrun, J. Thaddeus Beck, Yoshinori Ito, Denise A. Yardley, Ines Deleu, Alejandra Perez, Thomas Bachelot, Luc Vittori, Zhiying Xu, Pabak Mukhopadhyay, David Lebwohl, Gabriel N. Hortobágyi - New England Journal of Medicine 2011 cited by 2,828

  5. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

    Authors: François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc, Florence Dalenc, Jean‐Yves Pierga, Jean-Yves Pierga, Thibault de la Motte Rouge, Coraline Dubot, Jean‐Sébastien Frenel, Jean Marc Ferrero, Sylvain Ladoire, Sylvain Ladoire, Marie‐Ange Mouret‐Reynier, Alain Lortholary, Alain Lortholary, Camille Chakiba, Laëtitia Stefani, Jérôme Edouard Plaza, Florian Clatot, Luís Teixeira, Luis Teixeira, Véronique D'Hondt, Olfa Derbel, Claire Garnier-Tixidré, Jean-Luc Canon, Barbara Pistilli, Fabrice André, Laurent Arnould, Anne Pradines, Ivan Bièche, Céline Callens, Jérôme Lemonnier, Frédérique Berger, Suzette Delaloge, François‐Clément Bidard, Barbara Pistilli, Florence Dalenc, Barbara PISTILLI, Florence DALENC, Thomas BACHELOT, Coraline Dubot, Jean‐Sébastien Frenel, Jean-­Marc Ferrero, Sylvain Ladoire, Jean-Marc FERRERO, Marie‐Ange Mouret‐Reynier, Anne‐Claire Hardy‐Bessard, Alain Lortholary, Anne-Claire HARDY-BESSARD, Camille Chakiba, Laëtitia Stefani, P Soulié, Jean-Philippe Jacquin, Jérôme Edouard Plaza, Florian Clatot, Luís Teixeira, Florian CLATOT, Luis TEIXEIRA, Olfa Derbel, Claire Garnier Tixidre, Catherine Delbaldo, Lionel MOREAU, Caroline Cheneau, Jean-François Paitel, Chantal BERNARD-MARTY, Dominique Spaëth, Dominique Genet, Isabelle MOULLET, Nathalie BONICHON-LAMICHHANE, Laura DEIANA, Charlotte GREILSAMER, Laurence Venat‐Bouvet, Valérie Delecroix, Adrien MELIS, Hubert Orfeuvre, Suzanne Nguyen, Éric Legouffe, Alain Zannetti, Romuald Le Scodan, Nadine Dohollou, Philippe DALIVOUST, Olivier Arsène, Nathalie MARQUES, Thierry Petit, Delphine MOLLON, Jérôme Dauba, Nathalie Bonnin, François MORVAN, Miriam Gardner, Adina MARTI, Charles-Briac Levaché, Emma Lachaier, Mihaela ACHILLE, Christophe VALMAR, Ryan Bouaita, Jacques Médioni, Cyril Foa, Chantal BERNARD-MARTY, Francesco Del Piano, Michel GOZY and 19 more - The Lancet Oncology 2022 cited by 317

  6. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours

    Authors: Émilie Le Rhun, Matthias Gückenberger, Marion Smits, Reinhard Dummer, Thomas Bachelot, Felix Sahm, Norbert Galldiks, Evandro de Azambuja, Anna S. Berghoff, Philippe Métellus, Solange Peters, Yuna Hong, Frank Winkler, Dirk Schadendorf, Martin J. van den Bent, Joan Seoane, Rolf A. Stahel, Giuseppe Minniti, Pieter Wesseling, Michael Weller, Matthias Preusser - Annals of Oncology 2021 cited by 579

  7. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    Authors: Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei‐Chun Hsu, Stephen Chia - The Lancet Oncology 2021 cited by 349

  8. Genomic characterization of metastatic breast cancers

    Authors: François Bertucci, Charlotte K.Y. Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, Nadine Carbuccia, Jean Charles Soria, Alicia Tran Dien, Yahia Adnani, Maud Kamal, Sèverine Garnier, Guillaume Meurice, Marta Jimenez, Semih Doğan, Benjamin Verret, Max Chaffanet, Thomas Bachelot, Mario Campone, Claudia Lefeuvre, Hervé Bonnefoi, Florence Dalenc, Alexandra Jacquet, Maria Rosaria De Filippo, Naveen Babbar, Daniel Birnbaum, Thomas Filleron, Christophe Le Tourneau, Fabrice André - Nature 2019 cited by 750

  9. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

    Authors: Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Alicia Okines, Vandana G. Abramson, Philippe L. Bédard, Mafalda Oliveira, Volkmar Müller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O’Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer - Journal of Clinical Oncology 2020 cited by 549

  10. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

    Authors: Nancy U. Lin, Rashmi K. Murthy, Vandana G. Abramson, Carey K. Anders, Thomas Bachelot, Philippe L. Bédard, Virginia F. Borges, David Cameron, Lisa A. Carey, A. Jo Chien, Giuseppe Curigliano, Michael P. DiGiovanna, Karen A. Gelmon, Gabriel N. Hortobágyi, Sara A. Hurvitz, Ian E. Krop, Sherene Loi, Sibylle Loibl, Volkmar Müller, Mafalda Oliveira, Elisavet Paplomata, Mark D. Pegram, Dennis J. Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric P. Winer - JAMA Oncology 2022 cited by 197

  11. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

    Authors: Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, Meredith M. Regan, Fabrice André, Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner, Rita L. Hui, Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier - The Lancet Oncology 2019 cited by 477

  12. Genomics to select treatment for patients with metastatic breast cancer

    Authors: Fabrice André, Thomas Filleron, Maud Kamal, Fernanda Mosele, Mónica Arnedos, Florence Dalenc, Marie‐Paule Sablin, Mario Campone, Hervé Bonnefoi, Claudia Lefeuvre‐Plesse, William Jacot, Florence Coussy, Jean-­Marc Ferrero, George Emile, Marie‐Ange Mouret‐Reynier, Jean‐Christophe Théry, Nicolás Isambert, Alice Mège, Philippe Barthélémy, Benoît You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valéry Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Chérif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amélie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Gonçalvès, Thomas Bachelot, Ivan Bièche - Nature 2022 cited by 168

  13. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

    Authors: Fernanda Mosele, Bojana Stefanovska, Amélie Lusque, Alicia Tran Dien, Ingrid Garberis, Nathalie Droin, Christophe Le Tourneau, Marie‐Paule Sablin, Ludovic Lacroix, Diego Enrico, Isabelle Miran, Cécile Jovelet, Ivan Bièche, Jean‐Charles Soria, François Bertucci, Hervé Bonnefoi, Mario Campone, Florence Dalenc, Thomas Bachelot, Alexandra Jacquet, Marta Jimenez, Fabrice André - Annals of Oncology 2020 cited by 320

  14. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

    Authors: Michael Gobert, Isabelle Treilleux, Nathalie Bendriss‐Vermare, Thomas Bachelot, Sophie Goddard‐Léon, Vanessa Arfi, Cathy Biota, Anne Claire Doffin, Isabelle Durand, Daniel Olive, Solène Perez, Nicolas Pasqual, Christelle Fauré, Isabelle Ray‐Coquard, Alain Puisieux, Christophe Caux, Jean‐Yves Blay, Christine Ménétrier‐Caux - Cancer Research 2009 cited by 744

  15. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Authors: Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke, Catherine Sebban, Axel Le Cesne, Ian Judson, Olivier Trédan, Jaap Verweij, Pierre Biron, Sana Intidhar Labidi‐Galy, Jean‐Paul Guastalla, Thomas Bachelot, David Pérol, Sylvie Chabaud, Pancras C.W. Hogendoorn, Philippe A. Cassier, Armelle Dufresne, Jean‐Yves Blay - Cancer Research 2009 cited by 797

  16. Treatment strategies for breast cancer brain metastases

    Authors: Caroline Bailleux, Lauriane Eberst, Thomas Bachelot - British Journal of Cancer 2020 cited by 238

  17. Efficacy of PI3K inhibitors in advanced breast cancer

    Authors: B. Verret, Javier Cortés, Thomas Bachelot, Fabrice André, Mónica Arnedos - Annals of Oncology 2019 cited by 217

  18. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

    Authors: Thomas Bachelot, Gilles Romieu, Mario Campone, Véronique Dièras, Claire Cropet, Florence Dalenc, Marta Jimenez, Émilie Le Rhun, Jean‐Yves Pierga, Anthony Gonçalvès, Marianne Leheurteur, Julien Dômont, Maya Gutierrez, Hervé Curé, Jean-­Marc Ferrero, C. Labbé-Devilliers - The Lancet Oncology 2012 cited by 742

  19. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

    Authors: Aditya Bardia, Komal Jhaveri, Seock‐Ah Im, Sònia Pernas, Michelino De Laurentiis, Shusen Wang, Noelia Martínez-Jáñez, Giuliano Borges, David W. Cescon, Masaya Hattori, Yen‐Shen Lu, Erika Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M. Fairhurst, Sabrina S. Khan, Neelima Denduluri, Hope S. Rugo, Binghe Xu, Barbara Pistilli, for the TROPION-Breast01 Investigators, Betiana Romitelli, Ernesto Korbenfeld, Cristian Buono, Arturo Barbero, Geronimo Rosselli, Sergio Daniele, Sandra Anabel Ostoich, Hans Wildiers, Kevin Punie, Joëlle Collignon, Guy Jérusalem, Andrea Gombos, Giuliano Borges, Pedro Emanuel Rubini Liedke, Marcelle Goldner Cesca, Patrícia Medeiros Milhomem Beato, Laura Testa, Hélio Pinczowski, Liane Rapatoni, Debora de Melo Gagliato Jardim, José Bines, David W. Cescon, Jamil Asselah, Andre Blais, Joanne Yu, Jennifer Friedmann, Cristiano Ferrario, Binghe Xu, Shusen Wang, Qingyuan Zhang, ZeFei Jiang, Zhongsheng Tong, Quchang Ouyang, Jingfen Wang, Tingjing Yao, Yongsheng Wang, Xiaojia Wang, Meili Sun, Hui Li, Shu Wang, Yuan Sheng, Aimin Zang, Zhang Zhanmin, Wenyan Chen, Xian Wang, Zhong Ouyang, Wěi Li, Barbara Pistilli, Thomas Bachelot, Mony Ung, Cristian Villanueva, Delphine Garbay, Anne-Claire Hardy-Bessard, Audrey Mailliez, Stéphanie Bécourt, William Mina, Thomas Decker, Julia Radosa, Andreas Schneeweiß, Michael Braun, Bahriye Aktas, Gábor Rubovszky, Zsuzsanna Pápai, Tibor Csőszi, Yousuf Al-Farhat, Ankit Patel, Vineet Govinda Gupta, Richu Sharma, Chandrakanth Mosale Venkatesha, Shailesh Bondarde, Somnath Roy, Nikhil Ghadyalpatil, Lalit Sen Sharma, Rajani Priya Yedla, Michelino De Laurentiis, Ida Paris and 101 more - Journal of Clinical Oncology 2024 cited by 140

  20. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

    Authors: Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, PierFranco Conte, Véronique Dièras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders - Clinical Cancer Research 2020 cited by 198

  21. Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

    Authors: François‐Clément Bidard, William Jacot, Nicolas Kiavué, Sylvain Dureau, Amir Kadi, Etienne Brain, Thomas Bachelot, Hugues Bourgeois, Anthony Gonçalves, Sylvain Ladoire, H. Naman, Florence Dalenc, Joseph Gligorov, Marc Espié, George Emile, Jean-­Marc Ferrero, Delphine Loirat, Sophie Frank, Luc Cabel, Véronique Dièras, Laure Cayrefourcq, Cécile Simondi, Frédérique Berger, Catherine Alix‐Panabières, Jean‐Yves Pierga - JAMA Oncology 2020 cited by 178

  22. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

    Authors: Thomas Bachelot, Thomas Filleron, Ivan Bièche, Mónica Arnedos, Mario Campone, Florence Dalenc, Florence Coussy, Marie‐Paule Sablin, Marc Debled, Claudia Lefeuvre‐Plesse, Anthony Gonçalvès, Marie‐Ange Mouret‐Reynier, William Jacot, Benoît You, Philippe Barthélémy, Benjamin Verret, Nicolás Isambert, X. Tchiknavorian, Christelle Lévy, Jean‐Christophe Théry, Tifenn L’Haridon, Jean-­Marc Ferrero, Alice Mège, Francesco Del Piano, Étienne Rouleau, Alicia Tran-Dien, Julien Adam, Amélie Lusque, Marta Jimenez, Alexandra Jacquet, Ingrid Garberis, Fabrice André - Nature Medicine 2021 cited by 158

  23. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

    Authors: Javier Cortés, Sara A. Hurvitz, Seock‐Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung‐Bae Kim, Joanne Chiu, Jose L. Pedrini, Wěi Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Hamilton - Nature Medicine 2024 cited by 128

  24. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    Authors: Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N. Schwartz, Timothy Pluard, Francesco Ricci, William R. Gwin, Christelle Lévy, Ursa Brown‐Glaberman, Jean-­Marc Ferrero, Maaike de Boer, Sung‐Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik Jakobsen, Einav Nili Gal‐Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar, on behalf of the SOPHIA Study Group - Journal of Clinical Oncology 2022 cited by 80